An RCT of 19G EBUS-TBNA Needle in Suspected Sarcoidosis

NCT04770948 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-11-29

No results posted yet for this study

Summary

Sarcoidosis is an idiopathic disorder characterized by granulomatous inflammation involving various organ systems. The lung and mediastinal lymph nodes are the most commonly involved structures in sarcoidosis. In the presence of intrathoracic lymph nodes, transbronchial needle aspiration (TBNA) is a useful diagnostic modality, which is now guided using endobronchial ultrasound (EBUS).

We hypothesize that the 19-gauge EBUS-TBNA needle will have a higher yield as compared to the conventional 22-gauge EBUS-TBNA needle in intrathoracic lymphadenopathy due to sarcoidosis. In this study, we plan to evaluate the yield and safety of the 19-gauge needle vs. the conventional 22-gauge EBUS-TBNA needle in patients with sarcoidosis.

Conditions

  • Sarcoidosis

Interventions

DEVICE

19 gauge needle

EBUS-TBNA performed using 19G needle

DEVICE

22 gauge needle

EBUS-TBNA performed using 22G needle

Sponsors & Collaborators

  • All India Institute of Medical Sciences

    collaborator OTHER
  • Apollo Hospitals Enterprise Limited

    collaborator OTHER
  • Jaipur Golden Hospital, New Delhi

    collaborator UNKNOWN
  • Rajiv Gandhi Cancer Institute & Research Center, India

    collaborator OTHER
  • Institute of Pulmonology, Medical Research, and Development, Mumbai

    collaborator UNKNOWN
  • All India Institute of Medical Sciences, Bhopal

    collaborator OTHER
  • Asian Institute of Gastroenterology, Hyderabad

    collaborator UNKNOWN
  • Yashoda Hospitals, Hyderabad

    collaborator UNKNOWN
  • City Clinic and Bhailal Amin General Hospital, Vadodara

    collaborator UNKNOWN
  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-02-28
Completion
2023-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770948 on ClinicalTrials.gov